Back to All Articles
Browse articles with tag: Pharmaceutial Industry
You must be logged in to create a new article
All Articles
Patexia Insight 157: Most Active Companies in Biosimilar Litigation (BPCIA Act)
In late August, we published our third annual ANDA Litigation Intelligence Report. We evaluated the stakeholders for Hatch-Waxman cases filed... Read More
Patexia Insight 152: Best Performing Brand and Generic Pharmas of 2022 (ANDA)
Last month, we released our third annual ANDA Litigation Intelligence Report evaluating all stakeholders in ANDA/Hatch-Waxman cases filed over the... Read More
Patexia Insight 151: ANDA Litigators Who Moved in the Last 12 Months
In late August we released our third annual ANDA Litigation Intelligence Report. The report covered the ANDA litigation landscape by... Read More
Pedram Sameni
Aug 18, 2022
Patexia Insight 148: ANDA Litigation Grows in the First Half of 2022
This morning we released our third annual ANDA Litigation Intelligence Report. The report covers high-level statistics related to Hatch-Waxman litigation... Read More
Mikele Bicolli
Jul 27, 2022
The Benefits and Effects of Hatch- Waxman Act Four Decades Later
In early 1983, Bolar Pharmaceutical Inc. wanted to bring a generic version of the Dalmane drug, a sleeping pill, to... Read More
Mikele Bicolli
Jul 13, 2022
Patenting Small and Large Molecule Drugs
  Small molecule drugs have been the norm for much of medicine’s history. Only in the past decade has there... Read More